Symbols / TXG Stock $21.20 -1.49% 10x Genomics, Inc.

Healthcare • Health Information Services • United States • NMS
TXG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Health Information Services
CEO Dr. Serge Saxonov Ph.D.
Exch · Country NMS · United States
Market Cap 2.69B
Enterprise Value 2.23B
Income -22.66M
Sales 638.78M
FCF (ttm) 124.55M
Book/sh 6.24
Cash/sh 4.25
Employees 1,178
Insider 10d —
IPO Sep 12, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 106.00
PEG —
P/S 4.21
P/B 3.40
P/C —
EV/EBITDA -72.81
EV/Sales 3.50
Quick Ratio 5.25
Current Ratio 5.90
Debt/Eq 9.99
LT Debt/Eq —
EPS (ttm) -0.17
EPS next Y 0.20
EPS Growth —
Revenue Growth -2.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -4.48%
ROE -2.98%
ROIC —
Gross Margin 69.68%
Oper. Margin -11.30%
Profit Margin -3.55%
Shs Outstand 116.88M
Shs Float 115.09M
Insider Own 1.67%
Instit Own 111.14%
Short Float 19.00%
Short Ratio 6.57
Short Interest 16.25M
52W High 26.45
vs 52W High -19.83%
52W Low 8.06
vs 52W Low 162.86%
Beta 2.05
Impl. Vol. 75.54%
Rel Volume 1.08
Avg Volume 2.51M
Volume 2.72M
Target (mean) $25.23
Tgt Median $25.00
Tgt Low $20.00
Tgt High $32.00
# Analysts 13
Recom Buy
Prev Close $21.52
Price $21.20
Change -1.49%
About

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.23
Mean price target
2. Current target
$21.20
Latest analyst target
3. DCF / Fair value
$19.18
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$21.20
Low
$20.00
High
$32.00
Mean
$25.23

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 main Morgan Stanley Equal-Weight → Equal-Weight $22
2026-05-12 main JP Morgan Neutral → Neutral $20
2026-04-20 main Canaccord Genuity Buy → Buy $32
2026-04-20 main B of A Securities Neutral → Neutral $30
2026-04-14 main Barclays Overweight → Overweight $30
2026-04-07 main Citigroup Neutral → Neutral $24
2026-03-31 up William Blair Market Perform → Outperform —
2026-03-02 main Stifel Buy → Buy $25
2026-02-20 main UBS Neutral → Neutral $20
2026-02-13 main Stifel Buy → Buy $20
2026-02-13 main TD Cowen Hold → Hold $19
2026-01-27 main Leerink Partners Market Perform → Market Perform $20
2026-01-16 main Leerink Partners Market Perform → Market Perform $22
2026-01-07 main Leerink Partners Market Perform → Market Perform $20
2026-01-07 main TD Cowen Hold → Hold $18
2025-12-22 main Canaccord Genuity Buy → Buy $20
2025-12-15 main Barclays Overweight → Overweight $22
2025-12-11 down Citigroup Buy → Neutral $18
2025-12-02 down Morgan Stanley Overweight → Equal-Weight $20
2025-11-11 main Piper Sandler Neutral → Neutral $19
News
RSS: Latest TXG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 SAXONOV SERGE WILSON Chief Executive Officer — 5,000 $24.56 $122,784
2026-03-24 SAXONOV SERGE WILSON Chief Executive Officer — 15,000 $19.13 $288,908
2026-03-03 SAXONOV SERGE WILSON Chief Executive Officer — 2,750 $0.00 $0
2026-03-02 SAXONOV SERGE WILSON Chief Executive Officer — 16,152 $22.67 $367,097
2026-02-26 SAXONOV SERGE WILSON Chief Executive Officer — 157,895 $0.00 $0
2026-02-26 HINDSON BENJAMIN J President — 88,816 $0.00 $0
2026-02-26 TAICH ADAM Chief Financial Officer — 106,579 $0.00 $0
2026-02-25 TEICHMANN SARAH A. Director — 7,579 $19.41 $147,108
2026-02-23 HINDSON BENJAMIN J President — 7,826 $18.58 $145,379
2026-02-23 TAICH ADAM Chief Financial Officer — 8,968 $18.58 $166,593
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
642.82
+5.25%
610.78
-1.28%
618.73
+19.81%
516.41
Operating Revenue
642.82
+5.25%
610.78
-1.28%
618.73
+19.81%
516.41
Cost Of Revenue
198.94
+1.34%
196.30
-6.26%
209.41
+73.95%
120.39
Reconciled Cost Of Revenue
198.94
+1.34%
196.30
-6.26%
209.41
+73.95%
120.39
Gross Profit
443.88
+7.09%
414.48
+1.26%
409.31
+3.36%
396.02
Operating Expense
554.77
-8.91%
609.04
-0.75%
613.66
+8.81%
563.97
Research And Development
238.63
-9.85%
264.70
-2.08%
270.33
+1.76%
265.67
Selling General And Administration
316.13
-8.19%
344.34
+0.30%
343.33
+15.10%
298.30
Total Expenses
753.71
-6.41%
805.34
-2.15%
823.08
+20.27%
684.35
Operating Income
-110.89
+43.01%
-194.56
+4.79%
-204.35
-21.68%
-167.94
Total Operating Income As Reported
-60.98
+68.65%
-194.56
+26.67%
-265.33
-57.99%
-167.94
EBITDA
3.91
+102.92%
-133.99
+34.68%
-205.11
-59.63%
-128.49
Normalized EBITDA
-45.99
+65.68%
-133.99
+7.04%
-144.13
-12.17%
-128.49
Reconciled Depreciation
43.82
+0.25%
43.71
+0.20%
43.62
+32.15%
33.01
EBIT
-39.91
+77.54%
-177.70
+28.56%
-248.73
-54.02%
-161.50
Total Unusual Items
49.90
0.00
+100.00%
-60.98
0.00
Total Unusual Items Excluding Goodwill
49.90
0.00
+100.00%
-60.98
0.00
Special Income Charges
49.90
0.00
+100.00%
-60.98
0.00
Other Special Charges
-49.90
—
60.98
—
Restructuring And Mergern Acquisition
—
—
0.00
0.00
Net Income
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Pretax Income
-39.91
+77.54%
-177.70
+28.57%
-248.76
-53.58%
-161.97
Net Non Operating Interest Income Expense
20.05
+5.93%
18.93
+12.31%
16.85
+173.08%
6.17
Interest Expense Non Operating
0.00
-100.00%
0.00
-87.88%
0.03
-93.07%
0.48
Net Interest Income
20.05
+5.93%
18.93
+12.31%
16.85
+173.08%
6.17
Interest Expense
0.00
-100.00%
0.00
-87.88%
0.03
-93.07%
0.48
Interest Income Non Operating
20.05
+5.91%
18.93
+12.11%
16.89
+154.02%
6.65
Interest Income
20.05
+5.91%
18.93
+12.11%
16.89
+154.02%
6.65
Other Income Expense
50.93
+2563.96%
-2.07
+96.63%
-61.27
-30842.42%
-0.20
Other Non Operating Income Expenses
1.03
+149.83%
-2.07
-622.73%
-0.29
-44.44%
-0.20
Tax Provision
3.64
-26.18%
4.93
-22.24%
6.34
+57.26%
4.03
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
10.48
0.00
+100.00%
-12.81
0.00
Net Income Including Noncontrolling Interests
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Net Income From Continuing Operation Net Minority Interest
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Net Income From Continuing And Discontinued Operation
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Net Income Continuous Operations
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Normalized Income
-82.97
+54.57%
-182.63
+11.74%
-206.92
-24.65%
-166.00
Net Income Common Stockholders
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Diluted EPS
-0.35
+76.97%
-1.52
+30.28%
-2.18
-49.32%
-1.46
Basic EPS
-0.35
+76.97%
-1.52
+30.28%
-2.18
-49.32%
-1.46
Basic Average Shares
124.75
+3.57%
120.45
+2.81%
117.17
+2.90%
113.86
Diluted Average Shares
124.75
+3.57%
120.45
+2.81%
117.17
+2.90%
113.86
Diluted NI Availto Com Stockholders
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,041.37
+13.36%
918.64
-4.82%
965.14
-6.20%
1,028.98
Current Assets
684.45
+17.12%
584.39
-1.95%
596.02
-6.14%
635.03
Cash Cash Equivalents And Short Term Investments
523.41
+33.05%
393.40
+1.21%
388.69
-9.60%
429.98
Cash And Cash Equivalents
473.97
+37.75%
344.07
-4.24%
359.28
+63.50%
219.75
Other Short Term Investments
49.44
+0.22%
49.34
+67.74%
29.41
-86.01%
210.24
Receivables
82.49
-6.75%
88.47
-22.96%
114.83
+10.19%
104.21
Accounts Receivable
47.01
-46.49%
87.86
-23.49%
114.83
+10.19%
104.21
Gross Accounts Receivable
—
—
114.93
+10.18%
104.31
Allowance For Doubtful Accounts Receivable
—
—
-0.10
+0.00%
-0.10
Other Receivables
35.48
+5754.79%
0.61
—
—
Inventory
56.34
-32.21%
83.11
+12.75%
73.71
-9.71%
81.63
Raw Materials
16.02
-58.84%
38.93
+12.89%
34.48
-0.04%
34.50
Work In Process
17.14
-37.56%
27.44
+24.87%
21.98
-10.85%
24.65
Finished Goods
23.18
+38.52%
16.74
-2.96%
17.25
-23.29%
22.48
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
0.00
-100.00%
2.63
Other Current Assets
22.21
+14.42%
19.41
+3.31%
18.79
+13.34%
16.58
Total Non Current Assets
356.91
+6.78%
334.25
-9.45%
369.12
-6.30%
393.94
Net PPE
287.16
-7.35%
309.94
-10.15%
344.93
-3.97%
359.21
Gross PPE
440.62
+1.78%
432.90
-3.46%
448.42
+4.76%
428.04
Accumulated Depreciation
-153.46
-24.80%
-122.97
-18.82%
-103.49
-50.36%
-68.83
Properties
0.00
0.00
0.00
0.00
Land And Improvements
36.77
+0.00%
36.77
+0.00%
36.77
-0.04%
36.78
Buildings And Improvements
147.49
+0.27%
147.09
+0.72%
146.04
0.00
Machinery Furniture Equipment
103.26
+6.42%
97.04
+0.46%
96.60
+25.67%
76.86
Construction In Progress
2.93
-43.15%
5.15
-28.96%
7.25
-95.26%
153.00
Other Properties
60.45
+5.52%
57.29
-12.35%
65.36
-6.47%
69.88
Leases
89.72
+0.18%
89.57
-7.09%
96.41
+5.34%
91.52
Goodwill And Other Intangible Assets
66.84
+231.19%
20.18
-4.47%
21.13
-22.81%
27.37
Goodwill
4.51
+0.00%
4.51
+0.00%
4.51
+0.00%
4.51
Other Intangible Assets
62.33
+297.73%
15.67
-5.69%
16.62
-27.31%
22.86
Other Non Current Assets
2.91
-29.45%
4.13
+34.85%
3.06
-58.43%
7.37
Total Liabilities Net Minority Interest
245.04
+17.52%
208.50
-6.96%
224.10
+0.39%
223.24
Current Liabilities
153.45
+30.45%
117.63
-7.49%
127.16
-2.90%
130.96
Payables And Accrued Expenses
45.30
-7.27%
48.86
-28.71%
68.53
-18.72%
84.31
Payables
25.49
+22.29%
20.85
+0.29%
20.79
-19.05%
25.68
Accounts Payable
12.73
-1.36%
12.91
-17.98%
15.74
-27.14%
21.60
Other Payable
5.54
+84.61%
3.00
—
—
Current Accrued Expenses
19.81
-29.27%
28.01
-41.33%
47.74
-18.58%
58.63
Pensionand Other Post Retirement Benefit Plans Current
32.20
+30.33%
24.71
+15.28%
21.43
+7.11%
20.01
Total Tax Payable
7.22
+46.25%
4.94
-2.24%
5.05
+23.78%
4.08
Current Debt And Capital Lease Obligation
10.98
+18.30%
9.29
-19.40%
11.52
+27.49%
9.04
Current Capital Lease Obligation
10.98
+18.30%
9.29
-19.40%
11.52
+27.49%
9.04
Current Deferred Liabilities
23.90
+15.70%
20.66
+57.10%
13.15
+67.15%
7.87
Current Deferred Revenue
23.90
+15.70%
20.66
+57.10%
13.15
+67.15%
7.87
Other Current Liabilities
41.06
+190.68%
14.13
+12.75%
12.53
+28.77%
9.73
Total Non Current Liabilities Net Minority Interest
91.58
+0.79%
90.87
-6.26%
96.94
+5.05%
92.28
Long Term Debt And Capital Lease Obligation
73.38
+0.07%
73.33
-12.55%
83.85
-2.66%
86.14
Long Term Capital Lease Obligation
73.38
+0.07%
73.33
-12.55%
83.85
-2.66%
86.14
Non Current Deferred Liabilities
10.50
-16.08%
12.51
+41.97%
8.81
+178.48%
3.17
Non Current Deferred Revenue
10.50
-16.08%
12.51
+41.97%
8.81
+178.48%
3.17
Other Non Current Liabilities
7.71
+53.27%
5.03
+17.64%
4.28
+43.65%
2.98
Stockholders Equity
796.33
+12.14%
710.13
-4.17%
741.04
-8.03%
805.74
Common Stock Equity
796.33
+12.14%
710.13
-4.17%
741.04
-8.03%
805.74
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
127.69
+4.42%
122.29
+2.68%
119.10
+3.39%
115.20
Ordinary Shares Number
127.69
+4.42%
122.29
+2.68%
119.10
+3.39%
115.20
Additional Paid In Capital
2,306.69
+5.92%
2,177.67
+7.49%
2,025.89
+10.14%
1,839.40
Retained Earnings
-1,510.59
-2.97%
-1,467.05
-14.22%
-1,284.42
-24.78%
-1,029.32
Gains Losses Not Affecting Retained Earnings
0.23
+145.64%
-0.49
-14.92%
-0.43
+90.10%
-4.33
Other Equity Adjustments
0.23
+145.64%
-0.49
-14.92%
-0.43
+90.10%
-4.33
Total Equity Gross Minority Interest
796.33
+12.14%
710.13
-4.17%
741.04
-8.03%
805.74
Total Capitalization
796.33
+12.14%
710.13
-4.17%
741.04
-8.03%
805.74
Working Capital
531.00
+13.76%
466.75
-0.45%
468.86
-6.99%
504.08
Invested Capital
796.33
+12.14%
710.13
-4.17%
741.04
-8.03%
805.74
Total Debt
84.36
+2.12%
82.61
-13.38%
95.37
+0.20%
95.18
Capital Lease Obligations
84.36
+2.12%
82.61
-13.38%
95.37
+0.20%
95.18
Net Tangible Assets
729.49
+5.73%
689.95
-4.16%
719.92
-7.51%
778.37
Tangible Book Value
729.49
+5.73%
689.95
-4.16%
719.92
-7.51%
778.37
Non Current Accrued Expenses
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
136.05
+1941.57%
6.66
+143.85%
-15.20
+54.78%
-33.61
Cash Flow From Continuing Operating Activities
136.05
+1941.57%
6.66
+143.85%
-15.20
+54.78%
-33.61
Net Income From Continuing Operations
-43.54
+76.16%
-182.63
+28.41%
-255.10
-53.67%
-166.00
Depreciation Amortization Depletion
43.82
+0.25%
43.71
+0.20%
43.62
+32.15%
33.01
Depreciation
43.82
+0.25%
43.71
+0.20%
43.62
+32.15%
33.01
Depreciation And Amortization
43.82
+0.25%
43.71
+0.20%
43.62
+32.15%
33.01
Other Non Cash Items
-0.35
-166.16%
0.52
+22.48%
0.43
-78.18%
1.96
Stock Based Compensation
109.12
-22.47%
140.75
-15.69%
166.95
+22.00%
136.85
Asset Impairment Charge
2.07
-32.32%
3.05
-68.98%
9.85
0.00
Operating Gains Losses
—
0.00
-99.83%
1.72
+58.20%
1.09
Gain Loss On Investment Securities
—
0.00
-99.83%
1.72
—
Gain Loss On Sale Of PPE
—
—
—
1.09
Change In Working Capital
24.94
+1888.76%
1.25
-92.77%
17.34
+144.00%
-39.42
Change In Receivables
6.44
-76.10%
26.95
+353.94%
-10.61
+43.99%
-18.95
Changes In Account Receivables
41.31
+53.29%
26.95
+353.94%
-10.61
+43.99%
-18.95
Change In Inventory
27.95
+385.91%
-9.78
-224.22%
7.87
+137.14%
-21.19
Change In Prepaid Assets
-2.34
-23.25%
-1.90
+21.74%
-2.43
+45.96%
-4.50
Change In Payables And Accrued Expense
-7.28
+54.76%
-16.09
-172.20%
22.28
+142.38%
9.19
Change In Accrued Expense
-5.15
+59.54%
-12.74
-145.00%
28.30
+748.35%
3.34
Change In Payable
-2.13
+36.61%
-3.35
+44.26%
-6.02
-202.71%
5.86
Change In Account Payable
-2.13
+36.61%
-3.35
+44.26%
-6.02
-202.71%
5.86
Change In Other Working Capital
8.39
-43.53%
14.86
+79.18%
8.29
+85.82%
4.46
Change In Other Current Assets
0.69
+163.56%
-1.08
-59.88%
-0.68
-173.30%
0.93
Change In Other Current Liabilities
-8.91
+23.86%
-11.71
-58.49%
-7.39
+21.12%
-9.37
Investing Cash Flow
-13.44
+58.82%
-32.63
-124.44%
133.49
+138.04%
-350.89
Cash Flow From Continuing Investing Activities
-13.44
+58.82%
-32.63
-124.44%
133.49
+138.04%
-350.89
Net PPE Purchase And Sale
-5.93
+52.11%
-12.39
+74.50%
-48.60
+63.09%
-131.66
Purchase Of PPE
-5.93
+52.11%
-12.39
+74.50%
-48.60
+63.09%
-131.66
Capital Expenditure
-5.93
+55.69%
-13.39
+72.96%
-49.52
+62.39%
-131.66
Net Investment Purchase And Sale
1.76
+109.17%
-19.24
-110.51%
183.02
+185.03%
-215.23
Purchase Of Investment
-123.44
-152.55%
-48.88
0.00
+100.00%
-282.87
Sale Of Investment
125.20
+322.43%
29.64
-83.81%
183.02
+170.55%
67.64
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-4.00
Purchase Of Business
—
0.00
0.00
+100.00%
-4.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-1.00
-8.34%
-0.92
0.00
Purchase Of Intangibles
0.00
+100.00%
-1.00
-8.34%
-0.92
0.00
Net Other Investing Changes
-9.27
—
—
—
Financing Cash Flow
6.80
-37.67%
10.91
-20.16%
13.67
-13.58%
15.82
Cash Flow From Continuing Financing Activities
6.80
-37.67%
10.91
-20.16%
13.67
-13.58%
15.82
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
—
—
—
0.00
Proceeds From Stock Option Exercised
6.80
-37.67%
10.91
-43.98%
19.48
-8.21%
21.23
Net Other Financing Charges
—
—
-5.81
-7.49%
-5.41
Changes In Cash
129.41
+959.73%
-15.05
-111.41%
131.96
+135.79%
-368.68
Effect Of Exchange Rate Changes
0.48
+395.12%
-0.16
-396.97%
-0.03
+25.00%
-0.04
Beginning Cash Position
344.07
-4.24%
359.28
+58.03%
227.35
-61.86%
596.07
End Cash Position
473.97
+37.75%
344.07
-4.24%
359.28
+58.03%
227.35
Free Cash Flow
130.12
+2033.65%
-6.73
+89.60%
-64.72
+60.84%
-165.27
Interest Paid Supplemental Data
0.00
0.00
-100.00%
0.44
-48.16%
0.84
Income Tax Paid Supplemental Data
2.39
-57.61%
5.64
+14.49%
4.93
+25.53%
3.92
Amortization Of Securities
—
—
0.43
-50.98%
0.87
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category